On 13 July 2026 Incanthera announced board changes completing the restructuring begun in June. Laura Brogden, with the company since its 2010 spin-out from the University of Bradford, became executive chief financial officer. Werner Bürki, a former chief executive of the Swiss stock exchange, …
The interim results for the six months to 30 June 2026 showed revenue of £1.62m against £1.00m in the first half of 2025. Stripping out the £1.40m Haleon settlement, underlying revenue, principally US Eroxon royalties, was just £0.21m. The operating loss narrowed to £1.20m …
The decline appears to reflect a reassessment of valuation following optimism around proposed nationwide Medicare coverage for topical oxygen therapy. The proposed policy is an important milestone, but it remains subject to consultation and finalisation. Management has indicated that the current revenue trajectory may …
The decline reflects renewed concern about the pace and quality of revenue growth following a period of weaker-than-expected commercial performance. The company has faced reduced sales momentum in China, where export controls and changes to commercial operations have affected demand. Middle Eastern activity has …
The decline appears to reflect a combination of commercial concerns, profit-taking and weak sentiment toward smaller pharmaceutical companies rather than a newly announced clinical failure. Investors remain focused on whether growing prescription volumes can produce sufficient net revenue and cash flow.
The decline reflects continuing concern about the company’s revised outlook rather than a deterioration in the long-term scientific relevance of its technology. Oxford BioMedica previously indicated that some clients were taking a more staged approach when ordering work packages. Certain programmes were deferred because …
ProBiotix Health has moved into a particularly important stage of its development.
AOTI, Inc. is firmly in focus on1 September 2026 after LSE:AOTI fell 12.42%, making the medical-technology company one of the notable decliners in the current market session.
Futura Medical plc is firmly in focus on1 September 2026 after LSE:FUM fell 12.42%, with investors reacting to the company's latest interim results and, most importantly, the warning that additional funding will be required to extend its cash runway beyond October 2026.
Proteome Sciences plc is firmly in focus on1 September 2026 after LSE:PRM fell 15.48%, making the company one of the notable decliners in the current market session.